Abivax (ABVX) Income from Discontinued Operations (2025 - 2026)
Abivax's (ABVX) quarterly Income from Discontinued Operations came in at 266930.01 in Q1 2026, up 96.05% quarter-over-quarter from 6751452.39 in Q4 2025.
Abivax (ABVX) Income from Discontinued Operations (2025 - 2026) Analysis & Trends
Abivax's Income from Discontinued Operations history runs 2 years deep, the most recent figure standing at 266930.01 for Q1 2026.
- On a quarterly basis, Income from Discontinued Operations changed N/A year-over-year to 266930.01 in Q1 2026; TTM through Mar 2026 was 7018382.39, a N/A change from a year earlier, with the FY2025 full-year figure at 6751452.39, changed N/A from the prior year.
- Income from Discontinued Operations rose to 266930.01 in Q1 2026 per ABVX's latest filing, from 6751452.39 in the prior quarter.
- Across five years, Income from Discontinued Operations topped out at 266930.01 in Q1 2026 and bottomed at 6751452.39 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Abivax | 9.98 Bn | 9.98 Bn | - | -266,930.01 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -266,930.01 |
| Dec 31, 2025 | -6.75 Mn |